BOT — Botanix Pharmaceuticals Share Price
Last trade - 00:00- AU$681.61m
- AU$634.04m
- AU$0.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 35.28 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.37 | ||
| Price to Tang. Book | 11.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,196.73 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.45% | ||
| Return on Equity | -56.99% | ||
| Operating Margin | -7099.72% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.17 | 0.1 | 0.04 | 0.17 | 0.6 | 24.3 | 104.2 | 25.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. It also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. It also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.
Directors
- Vincent Ippolito CHM
- Richard Peterson CFO (53)
- William Bosch EDR
- Matthew Callahan EDR
- Howie McKibbon OTH
- Clarence Young OTH
- Simon Robertson SEC
- Stewart Washer NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 21st, 1984
- Public Since
- January 24th, 1985
- No. of Shareholders
- 10,150
- No. of Employees
- 1
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,817,627,097
- Address
- Suite 3, 41-47 Colin Street, West Perth, PERTH, 6005
- Web
- https://botanixpharma.com/
- Phone
- +61 862850083
- Contact
- Hannah Howlett
- Auditors
- BDO Audit Pty Ltd
Latest News for BOT
Upcoming Events for BOT
Full Year 2025 Botanix Pharmaceuticals Ltd Earnings Release
Similar to BOT
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
As of Today at 18:41 UTC, shares in Botanix Pharmaceuticals are trading at AU$0.38. This share price information is delayed by 15 minutes.
Shares in Botanix Pharmaceuticals last closed at AU$0.38 and the price had moved by +114.29% over the past 365 days. In terms of relative price strength the Botanix Pharmaceuticals share price has outperformed the ASX All Ordinaries Index by +110.31% over the past year.
The overall consensus recommendation for Botanix Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBotanix Pharmaceuticals does not currently pay a dividend.
Botanix Pharmaceuticals does not currently pay a dividend.
Botanix Pharmaceuticals does not currently pay a dividend.
To buy shares in Botanix Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.38, shares in Botanix Pharmaceuticals had a market capitalisation of AU$681.61m.
Here are the trading details for Botanix Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: BOT
Based on an overall assessment of its quality, value and momentum Botanix Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Botanix Pharmaceuticals is AU$0.65. That is 73.33% above the last closing price of AU$0.38.
Analysts covering Botanix Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.01 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Botanix Pharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -9.49%.
As of the last closing price of AU$0.38, shares in Botanix Pharmaceuticals were trading -1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Botanix Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 35.28. The shares last closed at AU$0.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Botanix Pharmaceuticals' management team is headed by:
- Vincent Ippolito - CHM
- Richard Peterson - CFO
- William Bosch - EDR
- Matthew Callahan - EDR
- Howie McKibbon - OTH
- Clarence Young - OTH
- Simon Robertson - SEC
- Stewart Washer - NED